Why the study?
Targeted cancer therapies have improved survival, but overlap in signaling pathways between cancer and noncancer cells has led to systemic and cardiovascular toxicities.
What are the mechanisms, incidence, and potential cardioprotective strategies for heart failure associated with targeted cancer therapies?
What are the mechanisms, incidence, and potential cardioprotective strategies for heart failure associated with targeted cancer therapies?
This review summarizes the incidence, mechanisms, and potential cardioprotective strategies for heart failure induced by targeted cancer therapies.
Answers are grounded in this paper and cite their sources.
Supports cardio-oncology integration for targeted cancer therapy patients; leaves open optimal cardioprotective strategies for prospective trials.
Oncology has seen growing use of newly developed targeted therapies. Although this has resulted in dramatic improvements in progression-free and overall survival, challenges in the management of toxicities related to longer-term treatment of these therapies have also become evident. Although a targeted approach often exploits the differences between cancer cells and noncancer cells, overlap in signaling pathways necessary for the maintenance of function and survival in multiple cell types has resulted in systemic toxicities. In particular, cardiovascular toxicities are of important concern. In this review, we highlight several targeted therapies commonly used across a variety of cancer types, including HER2 (human epidermal growth factor receptor 2)+ targeted therapies, tyrosine kinase inhibitors, immune checkpoint inhibitors, proteasome inhibitors, androgen deprivation therapies, and MEK (mitogen-activated protein kinase kinase)/BRAF (v-raf murine sarcoma viral oncogene homolog B) inhibitors. We present the oncological indications, heart failure incidence, hypothesized mechanisms of cardiotoxicity, and potential mechanistic rationale for specific cardioprotective strategies.
No takes yet. Share an insight, caveat, or question.
Hahn et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: